Table 1
| Disease Site |
Study | Study Name | Open Date | Number of Active Institutions |
Number of Current IRBs |
|---|---|---|---|---|---|
| BREAST | S1007 | Breast,Adj,N1,Endocrine+/-Chemo | 15-JAN-11 | 408 | 206 |
| S1207 | Brst,Adj,Endocrine+/-Everolimus | 03-SEP-13 | 485 | 248 | |
| S1416 | Brst, TNBC/BRCA, Cis+/- ABT-888 | 07-JUL-16 | 267 | 124 | |
| S1418 | Breast, Adj, TNBC, MK-3475 (Pembrolizumab) | 15-NOV-16 | 366 | 149 | |
| A011106 | Breast, Neoadj, ALTERNATE study | 15-FEB-14 | 267 | 126 | |
| A011203 | Breast, Adv, Tam vs Endoxifen | 27-JAN-15 | 242 | 90 | |
| A011401 | Breast, adj, Stage II/III HER2-, weight loss | 29-AUG-16 | 261 | 147 | |
| B55 | Brst, Adj Olaparib for BRCA,TNBC | 03-JUL-14 | 422 | 194 | |
| E1Z11 | Brst,Genetic Predictors of AIMSS | 10-MAY-13 | 270 | 95 | |
| E2112 | Brst,Adv,Exemestane+/-Entinostat | 02-JAN-14 | 296 | 165 | |
| NRGBR003 | Brst,Adj,TNBC,AC -> WP +/- Carbo | 22-JAN-15 | 441 | 217 | |
| Breast | A011502 | Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo | 08-DEC-16 | 0 | 180 |
| CCD | S1415CD | TrACER CSF Standing Order Intervention for FN | 01-SEP-16 | 52 | 67 |
| S1417CD | Colorectal, Cost Cohort Study | 13-MAY-16 | 199 | 57 | |
| A011104 | Preoperative Breast MRI | 21-FEB-14 | 176 | 64 | |
| ERLYTX | S1609 | Rare Tumor, Comb Nivo/Ipi | 13-JAN-17 | 324 | 132 |
| A071102 | GBM, adj TMZ +/- Veliparib | 19-SEP-14 | 361 | 161 | |
| A071401 | Prog Meningiomas,SMO/AKT/NF2 Inhib | 06-AUG-15 | 234 | 102 | |
| ARST1321 | NonRhabdo STS,Pazopanib (PAZNTIS) | 16-MAY-14 | 254 | 121 | |
| EAY131 | MATCH | 12-AUG-15 | 436 | 230 | |
| GI | S1505 | Panc,Resect, Perioperative Chemo | 12-OCT-15 | 291 | 112 |
| S1513 | Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888 | 01-SEP-16 | 301 | 132 | |
| A021501 | Adeno Panc,Borderline Resect,Chemo vs ChemoRT | 01-DEC-16 | 0 | 13 | |
| E7208 | CRC,Adv, Irino/Cet+/-Ramucirumab | 20-FEB-14 | 203 | 87 | |
| EA2133 | Anal, local recur/met, Cis+5FU vs Taxol/Carbo | 29-JAN-16 | 0 | 32 | |
| EA2142 | GI NEC, Adv G3, EP vs TMZ + CAP | 06-NOV-15 | 185 | 70 | |
| N1048 | Rectal,LocalAdv,ChemoRT+/-FOLFOX | 13-JAN-12 | 0 | 167 | |
| NRGGI002 | Rectal, Ph II, Sensitization using TNT | 12-OCT-16 | 267 | 114 | |
| R0848 | Panc, Adj, Erlotinib v ChemoRT | 01-MAR-14 | 0 | 146 | |
| GU | S1314 | Blad, COXEN Neoadj. Chemo + Cyst | 11-JUL-14 | 214 | 111 |
| S1500 | pRCC,Adv, Sunitinib vs MET inhib | 05-APR-16 | 197 | 84 | |
| S1602 | Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG | 07-FEB-17 | 127 | 50 | |
| S1605 | Blad, BCG-Unresponsive NMIBC, Atezolizumab | 07-FEB-17 | 98 | 48 | |
| A031102 | GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) | 01-JUL-15 | 43 | 30 | |
| E2810 | Renal, Pazopanib vs Placebo | 17-APR-12 | 187 | 90 | |
| EA8141 | UTUC, HG, Chemo then Surg | 27-JAN-15 | 161 | 77 | |
| R0924 | Pros, NADT+WPRT vs. NADT+P&SV RT | 07-JUL-11 | 0 | 157 | |
| LEUK | S1312 | ALL, CD22+, REL/REF, Inotuzumab+CVP | 01-APR-14 | 4 | 5 |
| S1318 | ALL, Age 65+, Ph±, Blinatumomab | 12-JAN-15 | 177 | 70 | |
| S0919 | Rel AML: Pravastatin+Ida+Ara-C | 15-AUG-09 | 86 | 28 | |
| E1910 | BCR-ABL-neg, B ALL, Blinatumomab | 23-DEC-13 | 167 | 87 | |
| E2906 | AML, Age 60+, Clo vs Dauno+Cy | 24-FEB-11 | 154 | 78 | |
| NHLBIMDS | LEUK, National MDS Study | 05-APR-16 | 57 | 23 | |
| LUNG | S1400 | SCCA,Adv, Biomarker Master | 15-JUN-14 | 437 | 222 |
| S1400G | HRRD: Talazoparib (BMN 673) | 07-FEB-17 | 434 | 216 | |
| S1400I | Non-Match: Nivo + Ipi vs Nivo | 18-DEC-15 | 437 | 221 | |
| S1403 | Adv,EGFR-mt,Afatinib+/-Cetuximab | 25-MAR-15 | 227 | 92 | |
| 8811 | NSCLC, Stage III,ChemoRT+ABT-888 | 02-JAN-13 | 144 | 51 | |
| A081105 | ALCHEMIST1, EGFR mut, Erlotinib | 02-JAN-14 | 0 | 253 | |
| A151216 | ALCHEMIST0 - screening | 06-FEB-14 | 461 | 253 | |
| C140503 | NSCL, Lobect v Sublobar resect | 09-JUL-07 | 104 | 53 | |
| C30610 | SCLC, Thoracic RT | 21-MAR-08 | 244 | 114 | |
| E4512 | ALCHEMIST2, ALK mut, Crizotinib | 18-AUG-14 | 465 | 252 | |
| EA5142 | ALCHEMIST3, Non-match, Nivolumab | 16-MAY-16 | 443 | 234 | |
| NRGCC003 | SCLC, PCI or HA-PCI | 07-DEC-15 | 324 | 137 | |
| R1306 | NSCLC,Adv,ALK/EGFR,TargetAgents | 04-NOV-13 | 157 | 69 | |
| LYMPH | A051301 | ABC DLBCL, Auto HCT and Ibrutinib/Placebo | 15-JUL-16 | 120 | 49 |
| MELAN | S1320 | Adv, BRAF mut, Inter v Contin | 22-JUL-14 | 243 | 104 |
| S1404 | Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 | 15-OCT-15 | 413 | 175 | |
| S1512 | Melan, Adv, Desmoplastic, MK-3475 (pembro) | 20-OCT-16 | 62 | 26 | |
| EA6134 | Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T | 15-DEC-15 | 338 | 140 | |
| EA6141 | Melan, Avd, Nivolumab+Ipi ± Sargmostim | 01-MAR-16 | 298 | 120 | |
| MMYEL | E1A11 | MM, frontline, BLD vs CLD | 22-NOV-13 | 299 | 129 |
| E3A06 | AMM, Lenalidomide vs Observation | 08-NOV-10 | 272 | 125 | |
| OTHER | A091202 | Sarc, Efatutazone vs Placebo, Unresect ,Lipo | 02-SEP-14 | 54 | 30 |
| A091304 | Adv Sarc, MLN0128 v Pazopanib, PhI/II | 26-JAN-15 | 179 | 64 | |
| A091305 | HN, Adv, Thyroid PPAR agonist + Chemo | 01-SEP-14 | 93 | 30 | |
| A091401 | Sarc, | 18-JUN-15 | 199 | 78 | |
| A091404 | HN, AR+, Enzalutamide | 25-SEP-15 | 42 | 13 | |
| AOST1521 | Osteo CDX-011 in Rec/Ref Dz,Ph 2 | 02-JUL-15 | 46 | 32 | |
| E3311 | Oroph,Srg + Low or Std IMRT | 01-MAR-14 | 193 | 70 | |
| EA3132 | HN SCC, Stg III-IV , Adj RT +/- Cisp | 29-MAR-16 | 0 | 6 | |
| EAQ152 | Communication & education in tumor profiling | 26-SEP-16 | 168 | 81 | |
| G0281 | Ovar, Recur/prog LG, IC chemo vs trametinib | 27-FEB-14 | 0 | 17 | |
| NRGBN001 | HN, novel vs. std chemoradiation + chemo | 28-AUG-15 | 0 | 98 | |
| NRGGY004 | Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo | 04-FEB-16 | 340 | 153 | |
| NRGGY005 | OVAR, Cedir vs Olaparib vs C+O vs Std of Care | 06-FEB-16 | 143 | 64 | |
| NRGHN001 | Nasopharyngeal , Indiviual Tx EBV | 21-APR-14 | 192 | 68 | |
| NRGHN002 | HN, Adv, Orophyx RT vs RT+ Chemo | 27-OCT-14 | 287 | 104 | |
| R0724 | Cervical, Chem+RT +/- Adj. Chemo | 15-JAN-14 | 247 | 98 | |
| R0920 | HN, Adv, Postop IMRT ± Cetuximab | 24-DEC-13 | 356 | 157 | |
| R1216 | HN, Adv,Cis vs Dtx vs Dtx+Cetux | 18-MAR-13 | 279 | 121 | |
| PREV | S0820 | PACES: ColrecStg0-3 Blind DFMO/Sulindac | 01-MAR-13 | 323 | 117 |
| A211102 | Breast, Atypia via RPFNA, Metformin v Placebo | 01-FEB-15 | 29 | 7 | |
| A211201 | Breast Density, MA.32 companion | 22-AUG-12 | 21 | 12 | |
| EA1141 | Breast, Abbrev. MRI vs Digital Tomosynthesis | 02-SEP-16 | 0 | 5 | |
| SURV | S1316 | Compar. Effectiv. Trial for MBO | 09-MAR-15 | 13 | 15 |
| E1Q11 | EROS: Reproductive Health in Cancer Survivors | 30-SEP-15 | 0 | 35 | |
| SXQOL | A221101 | Glioma, Nuvigil/Placebo Fatigue | 03-JUN-13 | 216 | 91 |
| A221102 | Brst,AI Arthralgia,Testosterone | 07-SEP-12 | 0 | 64 | |